Tibotec presents positive interim findings from Phase IIa hepatitis study
In interim findings from the first 28 days of treatment for the first cohort of 50 treatment naive hepatitis C virus plus (HCV+), genotype 1, patients (once daily
Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33, a clinical-stage anti-IL-33 monoclonal antibody, in a deal that includes potential development and sales milestone payments of up to around $560m.